SOHO 3rd Italian Conference
Avatar

SOHO Italy 2021 on MM: State of the Art Therapy in Europe

By SOHO 3rd Italian Conference FEATURING Claudio Cerchione
January 5, 2022
0 Comments
Login to view comments. Click here to Login

Featured Video

27:54
Bristol Myers Squibb Hematology

Importance of Maintenance Therapy in MM Patients Post Auto-HSCT

Feat. B. Randolph

Featured Video

28:15
Bristol Myers Squibb Hematology

Considerations for Continuous Therapy in Multiple Myeloma

Feat. D. Landau

Related Content

AUTOPLAY
15:24
SOHO 3rd Italian Conference

SOHO Italy 2021 on R/R MM Treatment in Europe

Feat. C. Cerchione
01:29
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on the Addition of Carfilzomib as a Thir…

Feat. C. Cerchione
16:57
SOHO Italy 1st School of Multiple Myeloma

Anti-CD38 in MM Daily Practice: How Can We Potentiate the Action of …

Feat. C. Cerchione
06:50
ecancer

EHA 2021 Highlights on KRd for Lenalidomide-Refractory MM

Feat. C. Cerchione
10:40
Claudio Cerchione

Frontline MM State of the Art: Can We Prolong PFS With D-VTd in ASCT…

19:13
SOHO Italy 1st School of Multiple Myeloma

Daratumumab in MM Daily Practice: Is It Becoming the New Backbone?

Feat. C. Cerchione
15:57
SOHO 3rd Italian Conference

SOHO Italy 2021 on CAR T in MM: Preliminary Data and Perspectives

Feat. C. Cerchione
17:29
SOHO Italy 1st Clinical and Biological School of CAR-T

How to Integrate CAR-T in the Clinical Scenario of Multiple Myeloma

Feat. C. Cerchione
26:05
SOHO Italy 1st School of Multiple Myeloma

Introducing Anti-CD38 in Daily Practice of MM: Updates on the GRIFFI…

Feat. C. Cerchione
36:30
Bristol Myers Squibb Hematology

A Physician Perspective on Treating NSCT NDMM

Feat. F. Davies
17:59
Parameswaran Hari

Delivering the Best Initial Treatment for Myeloma: Induction Therapy…

15:12
Yale Cancer Center

ASH 2021: Cellular Therapies in Myeloma

Feat. N. Bar
10:50
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Updates on the Efficacy and Safety of Cilta-Cel in R/R MM: …

Feat. A. Jakubowiak
33:28
Cleveland Clinic Taussig Cancer Institute

Management of Relapsed/Refractory Multiple Myeloma

Feat. F. Anwer
26:18
Morie Gertz

Treatment of Relapsed Myeloma: Overview of Approved Drugs & Opti…

16:00
Moffitt Cancer Center's 17th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

Moffitt Cancer Center Debate: How Much Is Too Much in NDMM - Triplet…

Feat. R. Baz
04:41
Joshua Richter

Examining Triplet Therapy in MM: Analysis of ELOQUENT-3 and MAIA Tri…

31:15
Claudio Cerchione

R/R MM State of the Art: Proteasome Inhibitors, IMiDs, HDACi, mAbs, …

23:18
Oncology Data Advisor

Can Diet and Nutrition Impact Multiple Myeloma Outcomes?

Feat. U. Shah, R. Banerjee
26:02
Moffitt Cancer Center's 17th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

2022 Novel Immune-Based Therapy for R/R MM: Interactive Case Discuss…

Feat. J. Brayer